Evidence map›Paper›PMID 34533278›Full record

ArticleJournal of cellular and molecular medicine2021

Nitazoxanide induced myocardial injury in zebrafish embryos by activating oxidative stress response.

Fanghua Gong, Tianzhu Shen, Jiangnan Zhang, Xuye Wang, Guoqiang Fan, Xiaofang Che, Zhaopeng Xu, Kun Jia, Yong Huang, Xiaokun Li and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05480878 (Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05480878 phase3completednot on this mapstarted 2022, after this paper: background citation

Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis

TypeinterventionalSponsorTanta UniversityRan2022 to 2023Enrolled90ConditionsRheumatoid ArthritisArmsPlacebo, Nitazoxanide 500Mg Oral Tablet, Escitalopram 10mg
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Zebrafish in Cardiovascular Disease Research: from Model to Application.International journal of biological sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Fanghua GongSchool of Pharmacy, Wenzhou Medical University, Wenzhou, China.ORCID 0000-0002-8905-4894
Tianzhu ShenSchool of Pharmacy, Wenzhou Medical University, Wenzhou, China.
Jiangnan ZhangSchool of Pharmacy, Wenzhou Medical University, Wenzhou, China.
Xuye WangSchool of Pharmacy, Wenzhou Medical University, Wenzhou, China.
Guoqiang FanSchool of Pharmacy, Wenzhou Medical University, Wenzhou, China.
Xiaofang CheCenter for drug screening and research, School of Geography and Environmental Engineering, Gannan Normal University, Ganzhou, Jiangxi, China.
Zhaopeng XuCenter for drug screening and research, School of Geography and Environmental Engineering, Gannan Normal University, Ganzhou, Jiangxi, China.
Kun JiaCenter for drug screening and research, School of Geography and Environmental Engineering, Gannan Normal University, Ganzhou, Jiangxi, China.
Yong HuangCenter for drug screening and research, School of Geography and Environmental Engineering, Gannan Normal University, Ganzhou, Jiangxi, China.
Xiaokun LiSchool of Pharmacy, Wenzhou Medical University, Wenzhou, China.
Huiqiang LuCenter for drug screening and research, School of Geography and Environmental Engineering, Gannan Normal University, Ganzhou, Jiangxi, China.
Wenzhou Medical University · CNGannan Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nitazoxanide (NTZ) is a broad-spectrum antiparasitic and antiviral drug (thiazole). However, although NTZ has been extensively used, there are no reports concerning its toxicology in vertebrates. This study used the zebrafish as a vertebrate model to evaluate the safety of NTZ and to analyse the related molecular mechanisms. The experimental results showed that zebrafish embryos exposed to NTZ had cardiac malformation and dysfunction. NTZ also significantly inhibited proliferation and promoted apoptosis in cardiomyocytes. Transcriptomic analysis used compared gene expression levels between zebrafish embryos in the NTZ treatment and the control groups identified 200 upregulated genes and 232 downregulated genes. Analysis by Kyoto encyclopaedia of genes and genomes (KEGG) and gene ontology (GO) showed that signal pathways on cardiomyocyte development were inhibited while the oxidative stress pathways were activated. Further experiments showed that NTZ increased the content of reactive oxygen species (ROS) in the hearts of zebrafish. Antioxidant gadofullerene nanoparticles (GFNPs) significantly alleviated the developmental toxicity to the heart, indicating that NTZ activated the oxidative stress response to cause embryonic cardiomyocyte injury in zebrafish. This study provides evidence that NTZ causes developmental abnormalities in the cardiovascular system of zebrafish.

Indexed as

AnimalsAnimals, Genetically ModifiedApoptosisCardiotoxicityComputational BiologyDisease Models, AnimalDisease SusceptibilityEmbryo, NonmammalianGene Expression ProfilingGene OntologyHeart InjuriesMyocytes, CardiacNitro CompoundsOxidative StressReactive Oxygen SpeciesSuperoxide DismutasenitazoxanideNitro CompoundsReactive Oxygen SpeciesSuperoxide DismutaseThiazolesCardiotoxicityNitazoxanideOxidative stressRNA-seqZebrafish

Identifiers

PMID34533278
PMCPMC8505840
OpenAlexW3201172596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.